
11/1/539307(039) YAK: 347.77/78

INTELLECTUAL PROPERTYAND DEVELOPMENT

LESSONS FROM RECENT ECONOMIC RESEARCH

> Editors Carsten Fink . Keith E. Maskus



CONTENTS

Editors' Preface	ix
Contributors	хi
Abbreviations and Acronyms	xiii
Why We Study Intellectual Property Rights and What We Have Learned Carsten Fink and Keith E. Maskus	1
INTELLECTUAL PROPERTY, TRADE, FDI, AND INTERNATIONAL LICENSING	
How Stronger Protection of Intellectual Property Rights Affects International Trade Flows Carsten Fink and Carlos A. Primo Braga	19
The Role of Intellectual Property Rights in Encouraging Foreign Direct Investment and Technology Transfer Keith E. Maskus	41
Intellectual Property Rights and U.S. and German International Transactions in Manufacturing Industries Carsten Fink	75
Intellectual Property Rights and Licensing: An Econometric Investigation Guifang (Lynn) Yang and Keith E. Maskus	111
The Composition of Foreign Direct Investment and Protection of Intellectual Property Rights: Evidence from Transition Economies Beata Smarzynska Javorcik	133
	Abbreviations and Acronyms Why We Study Intellectual Property Rights and What We Have Learned Carsten Fink and Keith E. Maskus INTELLECTUAL PROPERTY, TRADE, FDI, AND INTERNATIONAL LICENSING How Stronger Protection of Intellectual Property Rights Affects International Trade Flows Carsten Fink and Carlos A. Primo Braga The Role of Intellectual Property Rights in Encouraging Foreign Direct Investment and Technology Transfer Keith E. Maskus Intellectual Property Rights and U.S. and German International Transactions in Manufacturing Industries Carsten Fink Intellectual Property Rights and Licensing: An Econometric Investigation Guifang (Lynn) Yang and Keith E. Maskus The Composition of Foreign Direct Investment and Protection of Intellectual Property Rights: Evidence from Transition Economies

Part II	INTELLECTUAL PROPERTY EXHAUSTION AND PARALLEL TRAD	
7	Entering the Jungle of Intellectual Property Rights Exhaustion and Parallel Importation Carsten Fink	171
8	Parallel Imports in a Model of Vertical Distribution: Theory, Evidence, and Policy Keith E. Maskus and Yongmin Chen	189
9	Developing and Distributing Essential Medicines to Poor Countries: The DEFEND Proposal Mattias Ganslandt, Keith E. Maskus, and Eina V. Wong	207
Part III	INTELLECTUAL PROPERTY, MARKET STRUCTURE, AND INNOVATION	
10	Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry Carsten Fink	227
11	Strengthening Intellectual Property Rights in Lebanon Keith E. Maskus	259
12	Intellectual Property Rights and Economic Development in China Keith E. Maskus, Sean M. Dougherty, and Andrew Mertha	295
INDEX		333
Figures		
8.1	Wholesale Price and Parallel Imports	195
8.2	Profits and Trade Costs	197
8.3	Social Surplus	198
Tables		
2.1	Definition of High-Technology Aggregate	24
2.2	Maximum Likelihood Estimates for Total Nonfuel Imports	27
2.3	Maximum Likelihood Estimates for Total Nonfuel Exports	29
2.4	Maximum Likelihood Estimates for High-Technology Imports	31
2.5	Maximum Likelihood Estimates for High-Technology Exports	33
3.1	Total FD1 Flows, Selected Countries (US\$ million)	44
3.2	Net Receipts on Royalties, License Fees, Business Services,	
	and Direct Investment Income, Selected Countries (US\$ million)	46
3,3	U.S. FDI Position in Selected Countries (US\$ million)	47

3.4	U.S. FDI Position by Major Sector in Selected Countries,	
	1994 (US\$ million)	49
3.5	Indicators of Multinational Activity in U.S. High-Technology Industries, 1989	52
3.6	Percentage of Firms Claiming that the Strength or Weakness	
	of IPRs Has a Strong Effect on Whether Direct Investments	
	Will Be Made, by Type of Facility, 1991	57
3.7	Percentage of Firms Claiming that Intellectual Property	37
,,,	Protection Is Too Weak to Permit Types of Investment, 1991	58
3.8	Elasticities of Modes of Supply with Respect to Domestic	50
J.0	Characteristics and Policies	64
4.1	U.S. International Transactions in Total Manufacturing:	04
±.1	Ordinary Least Squares Estimates	83
4.2	U.S. International Transactions in Total Manufacturing:	0.5
4.2	Maximum Likelihood Estimates	84
4.9	U.S. International Transactions in Individual Manufacturing	04
4.3	Industries: OLS Estimates	86
		00
4.4	U.S. International Transactions in Four Manufacturing Industries:	89
4.5	Pooled Ordinary Least Squares Estimates	02
4.5	U.S. Arm's-Length Exports and Sales by Affiliates in Total	92
	Manufacturing: OLS Estimates	92
4.6	U.S. Arm's-Length Exports and Sales by Affiliates in Individual	0.1
	Manufacturing Industries: OLS Estimates	93
4 .7	U.S. Arm's-Length Exports and Sales by Affiliates in Three	or
	Manufacturing Industries: Pooled OLS Estimates	95
4.8	German Total Exports and FDI Stocks in Four Manufacturing	20
	Industries: Pooled OLS Estimates	98
4.9	German Receipts for Patents, Inventions, and Processes in Six	
	Manufacturing Categories: Tobit Maximum Likelihood Estimates	101
5.1	Summary Statistics and Correlation Coefficients (NT = 69)	121
5.2	Estimation of Determinants of Licensing Volumes	122
5.3	Fixed-Effects Model with Heteroskedasticity-Consistent	
	Standard Errors	128
6.1	Measures of IPR Protection	141
6.2	IPR Index Based on IIPA Special 301 Watch List	
	Recommendations	142
6.3	Probit Results with Ginarte-Park Index of Patent Rights	
	Protection	145
6.4	Probit Results with IPR Index	148
6.5	Bivariate Probit with Sample Selection: Manufacturing	
	versus Distribution Projects (Ginarte-Park Index)	152
6.6	Bivariate Probit with Sample Selection: Manufacturing	
	vs. Distribution Projects (IPR Index)	156

Contents

vii

viii Contents

6.A.1	Results of OLS Regressions	160
6.A.2	Multinomial Logit Results: Manufacturing versus	
	Distribution Projects versus No FD1	162
8.1	Summary of Exhaustion Regimes	193
8.2	Product Categories	201
8.3	Estimation of Vertical Pricing Model	203
9.1	Deaths and DALYs Caused by HIV/AIDS, TB, and Malaria,	
	1999 (thousands)	211
9.2	International Price Comparison for a Selection of HIV/AIDS	
	Drugs: Prices in South Africa, Sweden, and the United States,	
	March 2001 (in US\$)	213
9.3	International Price Comparison for a Selection of HIV/AIDS	
	Drugs: Prices as a Share of GDP Per Capita (percent)	214
10.1	Quinolones: Overview	239
10.2	Hypotensives: Overview	240
10.3	Quinolones—Calibrated Weight Parameters	242
10.4	Hypotensives—Calibrated Weight Parameters	243
10.5	Quinolones—Average Profit Margins (percent)	243
10.6	Hypotensives—Average Profit Margins (percent)	244
10.7	Quinolones-Simulation	246
10.8	Hypotensives—Simulation	247
10.9	Quinolones—Simulated Consumer Welfare Losses	
	(Rs thousands)	249
10.10	Hypotensives—Simulated Consumer Welfare Losses	
	(Rs thousands)	250
11.1	Static Effects of Stronger Patent and Trademark Protection	
	on Pharmaceuticals Firms	270
11.2	Simulated Effects of Stronger Copyrights on Software	279
11.3	Effects of Stronger Copyrights on Printing and Publishing	284
11.4	Effects of Stronger Copyrights on Music and Video,	
	and Film Industries	287
12.1	Estimates of Percentage Piracy Rates for Copyright	
	Goods, 1996–97	304
12.2	Patent Applications by Type and Nationality, 1990–2000	315
12.3	Patent Grants by Type and Nationality, 1990–2000	316
12.4	Patenting Indicators for Top 11 Patenting Regions, 1985-96	317
12.5	Trademark Applications and Registrations	318
12.6	Trademarking Indicators for Top 10 Trademarking	
	Regions, 1996	319
12.7	International Comparisons of Science and Technology	
	Indicators, Recent Years	320
12.8	Science and Technology Indicators by Region, 1995	321